Clinical Trials Logo

Filter by:
NCT ID: NCT04276558 Completed - Clinical trials for Neurotrophic Keratitis

REC 0/0559 Eye Drops for Treatment of Moderate and Severe Neurotrophic Keratitis in Adult Patients

Start date: October 13, 2020
Phase: Phase 2
Study type: Interventional

A phase 2 study, aiming to evaluate the efficacy, safety and pharmacokinetics of REC 0/0559 in treatment of Neurotrophic Keratitis in Adult Patient in Europe and United States of America.

NCT ID: NCT04276129 Completed - Wound Heal Clinical Trials

Early Healing of Oral Soft Tissues: a Clinical and Biomolecular Analysis. Part II

Start date: February 20, 2020
Phase: N/A
Study type: Interventional

The purpose of the present study is to evaluate the influence of the post-surgical chlorhexidine indication in the gene expression profile and cellular behavior in the early wound healing process -24 hours after injury- of the oral soft tissues. The main hypothesis is that the post-surgical use of chlorhexidine affects the gene expression and the celular behavior in the early wound healing process of the soft oral tissues.

NCT ID: NCT04275726 Recruiting - Clinical trials for Aortic Valve Stenosis

LANDMARK Trial: a Randomised Controlled Trial of Myval THV

LANDMARK
Start date: November 4, 2020
Phase: N/A
Study type: Interventional

The primary objective of this study (LANDMARK) is to compare the safety and effectiveness of the Myval THV Series with Contemporary Valves (Sapien THV Series and Evolut THV Series) in patients with severe symptomatic native aortic valve stenosis. This study will be done in total 768 subjects (384:384, Myval THV Series vs. Contemporary Valves) The randomisation will be carried out with an allocation ratio of 1:1 between Myval THV Series vs. Contemporary Valves (Sapien THV Series and Evolut THV Series)

NCT ID: NCT04275414 Completed - Clinical trials for Coronavirus Infections

Bevacizumab in Severe or Critical Patients With COVID-19 Pneumonia

BEST-CP
Start date: February 15, 2020
Phase: Phase 2
Study type: Interventional

The novel identified coronavirus (SARS-CoV-2) in 2019 causes an nationwide outbreak as well as public health crisis in China, and expands globally. Pulmonary edema is one of the most detrimental symptoms and usually presents in severe and critical coronavirus disease (COVID-19), resulting in dyspnea, acute lung injury (ALI) ,acute respiratory distress syndrome (ARDS), and even death. Recent evidence revealed higher levels of blood Vascular Endothelial Growth Factor (VEGF) in COVID-19 patients compared with healthy controls. VEGF is considered as the most potent vascular permeability inducers. Numerous studies have revealed that VEGF was a key factor and a potential therapeutic target in ALI and ARDS. Bevacizumab, an anti-VEGF drug, approved by the FDA on February 26, 2004 and widely used in clinical oncotherapy, is a promising drug for ALI/ARDS in COVID-19 through suppression of pulmonary edema.

NCT ID: NCT04274972 Recruiting - Pancreas Cancer Clinical Trials

The Microbiome of Pancreatic Cancer: "PANDEMIC" Study

PANDEMIC
Start date: February 1, 2020
Phase:
Study type: Observational [Patient Registry]

Microbiome in patients affected by pancreatic ductal adenocarcinoma may present specific and identifiable patterns. These variations could affect the surgical outcome and increase the risk of life-threatening infections supported by multidrug-resistant bacteria. The identification of microbial signatures with tumor specificity may have a potential role in postoperative risk stratification. Variation of pancreatic, intestinal or bile microbiome and their relationship can be investigated and measured as promising tools in order to predict and overcome the clinical and infectious burden imposed by MDR infections. The prospect of a potential role for probiotics to promote competition against the pathogens and to improve the gastrointestinal barrier integrity has also been raised. Moreover, if the bacterial composition in human PDAC was confirmed to be distinct from that of the normal pancreas, microbiome variation could be used as a potential biomarker, to assess the potential for malignancy in precursor neoplastic lesions. However, we believe that a preliminary and explorative study is necessary. The study aims to outline the pancreatic microbiome of patients who undergo upfront PD for resectable PDAC and to characterize the possible association between bacterial composition and the occurrence of post-operative complications, particularly POPF and IC.

NCT ID: NCT04274829 Completed - Thyroid Cancer Clinical Trials

Predictive Factors of Lymph Node Metastasis in Patients With Papillary Microcarcinoma of the Thyroid

Start date: January 2010
Phase:
Study type: Observational

Papillary thyroid microcarcinoma (PTMC), defined as a tumor with larger diameter ≤ 1 cm, is considered a tumor with an indolent course and an excellent prognosis. Nevertheless, the incidence of lymph node metastasis in PTMC is not negligible, reaching up to 65% in some series. The aim of this study was to assess the incidence of lymph node metastasis in patients with PTMC and to evaluate predictive factors for lymph node metastasis.

NCT ID: NCT04274712 Enrolling by invitation - Clinical trials for Acute Rejection of Cardiac Transplant

Non-invasive Test for Acute Rejection Identification in Heart Transplanted Patients

INNOGRAFTRS001
Start date: February 3, 2020
Phase:
Study type: Observational

Aim of the study is to test INNOGRAFT Heart Suite in a clinical setting, using a previously collected set of plasma samples from patients who underwent heart transplant and routinely or symptoms-based surveillance during the period 2016- 2019.

NCT ID: NCT04274023 Terminated - Sarcoma, Clear Cell Clinical Trials

Study on TSR-042 in Advanced Clear Cell Sarcoma

ACCeSs
Start date: January 29, 2024
Phase: Phase 2
Study type: Interventional

Phase II,single arm study designed to explore the activity of TSR-042, an immunotherapy agent, in patients with a diagnosis of advanced or metastatic clear cell sarcoma (CCS).

NCT ID: NCT04273945 Recruiting - Clinical trials for Pulmonary Arterial Hypertension

Outcome Study Assessing a 75 Milligrams (mg) Dose of Macitentan in Patients With Pulmonary Arterial Hypertension

UNISUS
Start date: June 30, 2020
Phase: Phase 3
Study type: Interventional

The purpose of this study is to demonstrate superiority of macitentan 75 milligrams (mg) in prolonging the time to the first clinical events committee (CEC)-adjudicated morbidity or mortality (M/M) event in participants with symptomatic pulmonary arterial hypertension (PAH) compared to macitentan 10 mg.

NCT ID: NCT04273711 Completed - Obesity Clinical Trials

Can Thyroidectomy be Considered Safe in Obese Patients?

Start date: December 1, 2019
Phase:
Study type: Observational

Obesity is a growing public health concern in most western countries. More and more patients with high body mass index (BMI) are undergoing surgical procedures of all kinds and, in this context, obese patients are undergoing thyroid surgery more than ever before. This study showed that obesity, in the field of thyroid surgery, is not associated with any increase of postoperative complications. Thus, it is possible to conclude that thyroidectomy can be performed safely in obese patients.